News Search Results
Jan 08, 2026, 08:38 ET Mercury Bio Launches MB-TIP™--Revolutionizing Immunotherapy with Intracellular Targeting
Mercury Bio Inc. , an immunology-driven biotechnology company developing intracellular therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's, today announced MB-TIP™ (Mercury
More news about: Mercury Bio Inc.
Jan 08, 2026, 08:31 ET Arkstone Taps Ian Campbell as CEO to Lead Next Phase of Growth and Innovation
M&ARALEIGH, N.C., Jan. 8, 2026 /PRNewswire/ -- Arkstone Medical Solutions, a biotechnology company transforming Clinical Decision Support (CDS) through "Expert-in-the-Loop" machine learning (ML) and artificial intelligence (AI), today
More news about: Arkstone
Jan 08, 2026, 08:30 ET Detecting and Characterizing RNA Drug Candidates to Accelerate Therapeutic Development, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Jan 08, 2026, 08:30 ET Veeva and BioMarin Form Long-Term Strategic Partnership
important new medicines and reach even more patients around the world."About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company
More news about: Veeva Systems
Jan 08, 2026, 08:30 ET Veeva and BioMarin Form Long-Term Strategic Partnership
important new medicines and reach even more patients around the world."About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company
More news about: Veeva Systems
Jan 08, 2026, 08:00 ET Flagship Pioneering Appoints Adrian Rawcliffe as CEO-Partner and CEO of Etiome
pioneering new therapeutic approaches position him well to accelerate Etiome's mission to pioneer preemptive healthcare."Rawcliffe is a seasoned biotechnology leader with more than two decades of experience steering high-growth organizations through scientific, strategic, and financial inflection points.
More news about: Flagship Pioneering
Jan 08, 2026, 08:00 ET Benchling and Lilly TuneLab Partner to Democratize Access to AI Models for Scientists Everywhere
benchling.com/biotech-ai-report-2026.About BenchlingBenchling's mission is to unlock the power of biotechnology. Founded in 2012, Benchling provides a unified, cloud-based platform trusted by more than 1,300 biotech companies worldwide, from pioneering startups
More news about: Benchling
Jan 08, 2026, 08:00 ET Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Jan 08, 2026, 07:30 ET KAHR Bio Announces Strong Topline Phase 2 Results for DSP107 in Combination with Anti-PD-L1 Therapy in Colorectal Cancer
MODI'IN, Israel, Jan. 8, 2026 /PRNewswire/ -- KAHR Bio (KAHR or the Company), a clinical-stage biotechnology company developing DSP107, a first-in-class, bispecific 4-1BB–targeted, next-generation T-cell engager, today announced topline results from its
More news about: KAHR Medical
Jan 08, 2026, 05:27 ET Immortal Dragons Comments on Longevity Regulation and Investment Trends Following FT Podcast Appearance
improving human healthspan. The fund currently supports more than 15 portfolio companies operating across diverse areas of longevity science and biotechnology. In addition to its investment activities, Immortal Dragons promotes longevity education and advocacy through book translation and publishing, translation
More news about: Immortal Dragons
Jan 08, 2026, 05:11 ET Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.For more information, please visit:
More news about: Arkbio
Jan 08, 2026, 04:53 ET Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD
including Roche, Genentech, the Scripps Research Institute, the Institute of Microbiology of Chinese Academy of Sciences, domestic and international biotechnology companies, as well as venture capital institutions.For more information, please visit:
More news about: Arkbio
Jan 08, 2026, 04:00 ET Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD
MUNICH, Jan. 8, 2026 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA)
More news about: Complement Therapeutics
Jan 08, 2026, 04:00 ET Life Sciences Talent and Consulting Strategist George Quinn Named Partner, Fractional Talent at Slone Partners
that, he was Senior Director of On-Demand & Interim Leadership at Heidrick & Struggles, overseeing key accounts across pharmaceuticals and biotechnology.Earlier in his career, Quinn held progressively senior commercial and leadership roles at Axiom and Medasource, where he served most recently
More news about: Slone Partners
Jan 08, 2026, 03:30 ET STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
precision oncology strategies.NOTES TO EDITORSAbout STORM TherapeuticsSTORM Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications to treat disease. Its world leading understanding of RNA modifying enzymes (RME)
More news about: STORM Therapeutics
Jan 08, 2026, 03:00 ET TECregen Raises CHF 10 Million in Seed Financing and Appoints Dr. Bo Rode Hansen as Chairman
lifeBASEL, Switzerland, Jan. 8, 2026 /PRNewswire/ -- TECregen, a biotechnology company pioneering thymus regeneration, today announced the successful completion of a CHF 10 million (∼EUR 10.7 million / USD 12.6 million) seed
More news about: TECregen AG
Jan 08, 2026, 03:00 ET Independent Dutch Study Further Validates Merlin CP-GEP Test for Melanoma Prognosis
and www.merlinmelanomatest.com.About SkylineDxSkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Jan 07, 2026, 20:19 ET Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present
More news about: Kodiak Sciences Inc.
Jan 07, 2026, 16:17 ET Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jan 07, 2026, 16:01 ET AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Jan 07, 2026, 15:04 ET LabConnect Establishes New Global Headquarters in Raleigh-Durham Area
Carolina, strengthening its footprint in the rapidly growing Research Triangle region, a leading center for Contract Research Organizations (CROs), biotechnology, and pharmaceutical companies. The new office will serve as a strategic base for executive leadership, commercial, operational, and technology teams
More news about: LabConnect
Jan 07, 2026, 15:04 ET LabConnect Establishes New Global Headquarters in Raleigh-Durham Area
Carolina, strengthening its footprint in the rapidly growing Research Triangle region, a leading center for Contract Research Organizations (CROs), biotechnology, and pharmaceutical companies. The new office will serve as a strategic base for executive leadership, commercial, operational, and technology teams
More news about: LabConnect
Jan 07, 2026, 11:00 ET Arbele Receives FDA Orphan Drug Designation for ARB1002, an Anti-CDH17 Antibody-Drug Conjugate for the Treatment of Pancreatic Cancer
SEATTLE, Jan. 7, 2026 /PRNewswire/ -- Arbele, a biotechnology company focused on developing innovative targeted cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation
More news about: Arbele
Jan 07, 2026, 10:30 ET Pramana Pharmaceuticals Awarded USD $1 Million from the Alzheimer's Association
global composition-of-matter IP estate.About Pramana PharmaceuticalsPramana Pharmaceuticals Inc. is a near-term clinical-stage biotechnology company developing next-generation oral small-molecule therapies targeting metabolic signaling pathways across neurodegenerative and cardio-metabolic
More news about: Pramana Pharmaceuticals Inc.
Jan 07, 2026, 10:30 ET Pharmaceutical Microfiltration Market worth $9.94 billion by 2030 | MarketsandMarkets™
(Sweden).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets